Austar Lifesciences's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
During the past 13 years, Austar Lifesciences's highest 3-Year average EPS without NRI Growth Rate was 237.50% per year. The lowest was -51.30% per year. And the median was -8.00% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Austar Lifesciences EPS (Diluted) Related Terms
Austar Lifesciences EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Austar Lifesciences's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a EPS (Diluted) of $0.01 as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Austar Lifesciences and its competitors.
Is Austar Lifesciences' EPS (Diluted) too high?
Austar Lifesciences' current EPS (Diluted) is $0.01. Overall, Austar Lifesciences has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EPS (Diluted) compare to ABT and SYK?
Austar Lifesciences' EPS (Diluted) of $0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Devices & Instruments company?
A good EPS (Diluted) depends on the Medical Devices & Instruments industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Austar Lifesciences and its competitors. Austar Lifesciences's current EPS (Diluted) is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current EPS (Diluted) is $0.01. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EPS (Diluted) is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
EPS (Diluted): $0.01
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
